CU20180129A7 - Anticuerpos anti-basigin humanizados - Google Patents
Anticuerpos anti-basigin humanizadosInfo
- Publication number
- CU20180129A7 CU20180129A7 CU2018000129A CU20180129A CU20180129A7 CU 20180129 A7 CU20180129 A7 CU 20180129A7 CU 2018000129 A CU2018000129 A CU 2018000129A CU 20180129 A CU20180129 A CU 20180129A CU 20180129 A7 CU20180129 A7 CU 20180129A7
- Authority
- CU
- Cuba
- Prior art keywords
- humanized anti
- sub
- acid sequence
- antigen binding
- binding fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
<p>La presente divulgación proporciona un anticuerpo anti-BASIGIN humanizado o fragmento de unión a antígeno del mismo, que comprende una región variable de cadena pesada (V<sub>H</sub>) que comprende una secuencia de áminoacidos de Ia SEQ ID NO: 1; opcionalmente comprende adicionalmente una región variable de cadena ligera (V<sub>L</sub>) que comprende una secuencia de aminoácidos de Ia SEQ ID NO: 2. La presente divulgación también proporciona una composición que comprende el anticuerpo anti-BASIGIN humanizado o fragmento de unión a antígeno del mismo, una secuencia de ácidos nucleicos aislada que codifica el anticuerpo anti-BASIGIN humanizado o fragmento de unión a antígeno del mismo, y un vector que comprende el ácido nucleico.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610285139.4A CN105820250B (zh) | 2016-04-29 | 2016-04-29 | 一种抗basigin人源化抗体及其应用 |
| PCT/CN2017/082713 WO2017186182A1 (en) | 2016-04-29 | 2017-05-02 | Humanized anti-basigin antibodies and the use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20180129A7 true CU20180129A7 (es) | 2019-06-04 |
| CU24556B1 CU24556B1 (es) | 2021-12-08 |
Family
ID=56528099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2018000129A CU24556B1 (es) | 2016-04-29 | 2017-05-02 | Anticuerpos anti-basigin humanizados |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US12240901B2 (es) |
| EP (1) | EP3448892A4 (es) |
| JP (2) | JP7099709B2 (es) |
| KR (1) | KR102369118B1 (es) |
| CN (2) | CN105820250B (es) |
| AU (1) | AU2017255888B2 (es) |
| CA (1) | CA3022308A1 (es) |
| CL (1) | CL2018003072A1 (es) |
| CO (1) | CO2018011663A2 (es) |
| CR (1) | CR20180515A (es) |
| CU (1) | CU24556B1 (es) |
| DO (1) | DOP2018000234A (es) |
| EC (1) | ECSP18084153A (es) |
| IL (1) | IL262588B2 (es) |
| MA (1) | MA44777A (es) |
| MX (1) | MX2018013176A (es) |
| MY (1) | MY196874A (es) |
| NI (1) | NI201800113A (es) |
| PE (1) | PE20190415A1 (es) |
| PH (1) | PH12018502293B1 (es) |
| RU (1) | RU2755150C2 (es) |
| SG (1) | SG11201809473QA (es) |
| TN (1) | TN2018000358A1 (es) |
| WO (1) | WO2017186182A1 (es) |
| ZA (1) | ZA201807132B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105820250B (zh) | 2016-04-29 | 2019-04-30 | 中国人民解放军第四军医大学 | 一种抗basigin人源化抗体及其应用 |
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| CN111690062B (zh) * | 2019-03-14 | 2024-07-16 | 复旦大学 | 针对恶性疟PfRh5靶点的全人源单克隆抗体及应用 |
| CN110964119A (zh) * | 2019-12-05 | 2020-04-07 | 沣潮医药科技（上海）有限公司 | 抗疟二聚体免疫粘附素、药物组合物和用途 |
| CN111420048B (zh) * | 2020-03-11 | 2023-09-19 | 中国人民解放军第四军医大学 | 抗basigin人源化抗体用于制备治疗新型冠状病毒肺炎药物的应用 |
| CN113549152B (zh) * | 2021-07-22 | 2023-06-20 | 中国人民解放军空军军医大学 | 一种抗basigin人源化抗体及其应用 |
| CN113925963B (zh) * | 2021-10-15 | 2023-08-11 | 江苏太平洋美诺克生物药业股份有限公司 | 一种稳定的包含抗cd147单克隆抗体的药物制剂 |
| CN119775410B (zh) * | 2025-03-11 | 2025-04-29 | 成都大熊猫繁育研究基地 | 一种抗大熊猫vegfa单克隆抗体、杂交瘤细胞株及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0990031B1 (en) * | 1997-01-14 | 2006-03-29 | Human Genome Sciences, Inc. | Tumor necrosis factor receptor 5 |
| IL154751A0 (en) * | 2000-08-03 | 2003-10-31 | Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals | |
| US20050214302A1 (en) * | 2004-03-25 | 2005-09-29 | Marian Nakada | Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis |
| CN100586960C (zh) * | 2006-06-23 | 2010-02-03 | 陈志南 | HAb18GC2单抗和其轻、重链可变区基因及应用 |
| WO2008070344A2 (en) * | 2006-10-27 | 2008-06-12 | Lpath, Inc. | Compositions and methods for binding sphingosine-1-phosphate |
| NZ601583A (en) * | 2007-05-21 | 2013-08-30 | Bristol Myers Squibb Co | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| KR20150126724A (ko) * | 2007-09-28 | 2015-11-12 | 추가이 세이야쿠 가부시키가이샤 | 혈장 중 반응속도가 개선된 항-글리피칸-3 항체 |
| CN101550416B (zh) * | 2008-03-18 | 2012-01-25 | 陈志南 | 人源化单抗Hu-ScFv18的轻、重链可变区基因和其编码多肽及其应用 |
| US8007808B2 (en) * | 2008-04-04 | 2011-08-30 | The Board Of Trustees Of The Univeristy Of Illinois | Composition and method for facilitating the internalization of a therapeutic agent into a cell |
| EP2303325A4 (en) * | 2008-05-23 | 2012-09-19 | Uti Limited Partnership | INHIBITION OF EMMPRIN TO TREAT MULTIPLE SCLEROSIS |
| WO2010087743A2 (en) * | 2008-12-30 | 2010-08-05 | Cellartis Ab | The use of a protein in stem cell and cancer applications |
| ES2677564T3 (es) * | 2009-06-19 | 2018-08-03 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Método y composición farmacéutica para su uso en el tratamiento de trastornos neurodegenerativos |
| JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ） |
| DK2510010T3 (en) * | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| WO2011112566A2 (en) * | 2010-03-11 | 2011-09-15 | Abbott Laboratories | Basigin binding proteins |
| CN104086654B (zh) * | 2014-07-04 | 2016-06-08 | 中国人民解放军第四军医大学 | 人源化修饰型抗CD147嵌合抗体HcHAb18及其应用 |
| CN105820250B (zh) * | 2016-04-29 | 2019-04-30 | 中国人民解放军第四军医大学 | 一种抗basigin人源化抗体及其应用 |
| JP2020511130A (ja) * | 2017-03-09 | 2020-04-16 | サイトメックス セラピューティクス インコーポレイテッド | Ｃｄ１４７抗体、活性化可能ｃｄ１４７抗体、ならびにその作製および使用の方法 |
-
2016
- 2016-04-29 CN CN201610285139.4A patent/CN105820250B/zh active Active
-
2017
- 2017-05-02 TN TNP/2018/000358A patent/TN2018000358A1/en unknown
- 2017-05-02 EP EP17788834.4A patent/EP3448892A4/en active Pending
- 2017-05-02 PH PH1/2018/502293A patent/PH12018502293B1/en unknown
- 2017-05-02 RU RU2018138053A patent/RU2755150C2/ru active
- 2017-05-02 KR KR1020187034365A patent/KR102369118B1/ko active Active
- 2017-05-02 WO PCT/CN2017/082713 patent/WO2017186182A1/en not_active Ceased
- 2017-05-02 MY MYPI2018703986A patent/MY196874A/en unknown
- 2017-05-02 JP JP2018556501A patent/JP7099709B2/ja active Active
- 2017-05-02 PE PE2018002253A patent/PE20190415A1/es unknown
- 2017-05-02 CN CN201780041146.2A patent/CN109476760B/zh active Active
- 2017-05-02 CR CR20180515A patent/CR20180515A/es unknown
- 2017-05-02 MX MX2018013176A patent/MX2018013176A/es unknown
- 2017-05-02 CA CA3022308A patent/CA3022308A1/en active Pending
- 2017-05-02 US US16/097,274 patent/US12240901B2/en active Active
- 2017-05-02 SG SG11201809473QA patent/SG11201809473QA/en unknown
- 2017-05-02 CU CU2018000129A patent/CU24556B1/es unknown
- 2017-05-02 MA MA044777A patent/MA44777A/fr unknown
- 2017-05-02 IL IL262588A patent/IL262588B2/en unknown
- 2017-05-02 AU AU2017255888A patent/AU2017255888B2/en active Active
-
2018
- 2018-10-25 ZA ZA2018/07132A patent/ZA201807132B/en unknown
- 2018-10-26 DO DO2018000234A patent/DOP2018000234A/es unknown
- 2018-10-29 NI NI201800113A patent/NI201800113A/es unknown
- 2018-10-29 CL CL2018003072A patent/CL2018003072A1/es unknown
- 2018-10-29 CO CONC2018/0011663A patent/CO2018011663A2/es unknown
- 2018-11-12 EC ECSENADI201884153A patent/ECSP18084153A/es unknown
-
2022
- 2022-03-24 JP JP2022047763A patent/JP2022084832A/ja active Pending
-
2025
- 2025-01-24 US US19/036,011 patent/US20250243273A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
| MX2025002735A (es) | Virus oncolitico que codifica un inhibidor de la molecula 4 asociada a linfocitos t citotoxicos (ctla-4) y su uso en el tratamiento de cancer | |
| MX366359B (es) | Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1). | |
| MX2019013387A (es) | Dominio de union a antigeno. | |
| MX2021011167A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| EA201792184A1 (ru) | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) | |
| NZ711451A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
| UY37694A (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| MX377716B (es) | Moduladores de aplnr y usos de estos. | |
| UY36536A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| CU24568B1 (es) | Anticuerpo inhibidor de masp-3 | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| AR105267A1 (es) | Anticuerpos de unión a tau | |
| ES2621874T3 (es) | Anticuerpos para MUC16 y métodos de uso de los mismos | |
| PE20230381A1 (es) | Proteina de union a rgma | |
| CO6700829A2 (es) | Moduladores novedosos y métodos de uso | |
| CO2017004753A2 (es) | Anticuerpos que se unen a ccr6 | |
| PH12021550244A1 (en) | Anti-btla antibody | |
| MX2016010995A (es) | Novedoso anticuerpo anti-presepsina. | |
| JOP20210100A1 (ar) | جسم مضاد أحادي النسيلة يرتبط على وجه التحديد بـ cd20 | |
| AR099604A1 (es) | Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso | |
| AR126364A2 (es) | Anticuerpos anti-cd3 y métodos de uso | |
| EA201892124A1 (ru) | Днк-конструкции антител и способы их применения |